Genfit Advances Liver Pipeline With Completed Phase 1 G1090N Study

Genfit (GNFTY) announced an update on their ongoing clinical study.

Study Overview

Genfit is running a Phase 1 clinical study to test a new capsule form of G1090N (nitazoxanide) in healthy adults. The official title is “A Phase 1, Open Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects.” The goal is to see how the drug moves through the body, how safe it is, and how well people tolerate it, as an early step toward using it in conditions like acute-on-chronic liver failure. This update matters because it moves Genfit’s pipeline beyond its core NASH heritage and adds optionality in serious liver disease.

Intervention/Treatment

The study tests G1090N, an oral drug based on nitazoxanide, given as capsules. Volunteers receive either a single dose or repeated doses over several days. The aim is to identify safe dose levels and understand how much drug gets into the bloodstream and for how long, laying the groundwork for future studies in patients with advanced liver conditions.

Study Design

This is an interventional trial, meaning participants are actively given a study drug. Allocation is non-randomized, so volunteers are placed into dose groups in a set order instead of by chance. The intervention model is sequential, with dose levels increasing step by step as safety data comes in. There is no blinding; both doctors and volunteers know which dose is being given. The main purpose is treatment-focused, but at this early stage the key aim is to gather safety and dosing data, not yet to prove clinical benefit.

Study Timeline

The study was first submitted on July 25, 2025, marking its official start in the clinical registry. The trial is listed as completed, indicating dosing and main data collection in healthy volunteers have finished. Primary completion, when the key safety and drug-level data are collected, aligns with this completed status and signals that first results should now be available to the company. The listing was last updated on January 15, 2026, showing that recent information has been reviewed and suggests the dataset is current and ready to inform next-step decisions.

Market Implications

For investors, completion of this Phase 1 study reduces early-stage risk around G1090N and supports the view that Genfit is quietly broadening its liver portfolio. While Phase 1 data alone rarely move a stock sharply, a clean safety and dosing profile can support sentiment, especially in a small- to mid-cap biotech like Genfit where pipeline diversification is key to valuation. The acute-on-chronic liver failure space remains underserved, with limited direct competition and high unmet need, so progress here could open a differentiated growth path versus peers more focused on fatty liver disease alone. Investors should watch for any follow-up Phase 2 initiation and partnering activity as potential catalysts, as these would signal confidence in commercial potential and may draw new specialist interest to GNFTY.

The study has been completed and recently updated, and further details are available on the ClinicalTrials.gov portal.

To learn more about GNFTY’s potential, visit the Genfit drug pipeline page.